These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7102502)

  • 21. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter.
    Fort S; Lewis MJ; Luscombe DK; John DN
    Br J Clin Pharmacol; 1994 May; 37(5):460-3. PubMed ID: 8054253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
    Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
    G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
    Jørgensen NP; Walstad RA
    Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of verapamil in man.
    Koike Y; Shimamura K; Shudo I; Saito H
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):37-47. PubMed ID: 432439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous quantitation of verapamil, norverapamil, and N-dealkylated metabolites in human plasma following oral administration.
    Kapur PA; Law T; Watson E
    J Chromatogr; 1985 Jan; 337(1):160-5. PubMed ID: 3980648
    [No Abstract]   [Full Text] [Related]  

  • 29. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.
    Carosella L; Menichelli P; Alimenti M; Zuccala G; Gemma A; Cocchi A; Carbonin PU
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):417-25. PubMed ID: 2487538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic availability of oral verapamil and effect on PR interval in man.
    Johnston A; Burgess CD; Hamer J
    Br J Clin Pharmacol; 1981 Sep; 12(3):397-400. PubMed ID: 7295469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats.
    Todd EL; Abernethy DR
    Biopharm Drug Dispos; 1987; 8(3):285-97. PubMed ID: 3593905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Wagner JG; Rocchini AP; Vasiliades J
    Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies.
    Abernethy DR; Todd EL; Mitchell JR
    Pharmacology; 1984; 29(5):264-8. PubMed ID: 6494236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
    Choi JS; Burm JP
    Arch Pharm Res; 2005 Apr; 28(4):483-7. PubMed ID: 15918524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].
    Woodcock BG; Wörner P; Rietbrock N; Schwabe L; Frömming KH
    Arzneimittelforschung; 1982; 32(12):1567-71. PubMed ID: 6891597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate.
    Klein GJ; Twum-Barima Y; Gulamhusein S; Carruthers SG; Donner AP
    Clin Cardiol; 1984 Sep; 7(9):474-83. PubMed ID: 6529866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of calcium channel blocking agents.
    Anderson P
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():43-57. PubMed ID: 2940799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical pharmacokinetics of verapamil.
    Hamann SR; Blouin RA; McAllister RG
    Clin Pharmacokinet; 1984; 9(1):26-41. PubMed ID: 6362951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.